Home
AI in Drug Discovery
13 March - 14 March 2023
AI in Drug Discovery

SAE Media Group’s 4th Annual Conference
AI in Drug Discovery
13-14 March, 2023 | Conference
-------------------------------------------------------------------------

With the recent pandemic highlighting the need for rapid drug discovery, AI has become an area of increased interest. This is driven by the ability to discover drugs through the use of machine and deep learning. The current challenges within the drug discovery industry include the significant time consumption and expenses involved. This conference will discuss the solutions to these problems with presentations and updates from leading industry experts.

AI in drug discovery is leading the way into a shorter, cheaper and more successful R&D era where compound generation is automated, drug synthesis is predictable and undruggable diseases are finally being targeted.
 

FEATURED SPEAKERS

Alexander Hillisch

Alexander Hillisch

Head of Global CADD, UCB
Chris Murray

Chris Murray

SVP Discovery Technology, Astex Pharmaceuticals
Darren Green

Darren Green

Head of Cheminformatics & Data Science, Senior Fellow, GSK
Haruna Iwaoka

Haruna Iwaoka

Senior Director, Astellas Pharma
Jag Heer

Jag Heer

Director of Medicinal Chemistry, UCB
Jan Wenzel

Jan Wenzel

Scientist Computational and Systems Toxicology, Sanofi-Aventis Deutschland GmbH
Jennifer Knight

Jennifer Knight

Director, Schrödinger
Martin Akerman

Martin Akerman

Chief Technical Officer, Envisagenics
Martin-Immanuel Bittner

Martin-Immanuel Bittner

Co-Founder and CEO, Arctoris
Paul Beroza

Paul Beroza

Distinguished Scientist, Genentech
Simone Fulle

Simone Fulle

Head of Molecular modelling & Design, Novo Nordisk A/S
Steve Gardner

Steve Gardner

CEO, PrecisionLife
Thierry Dorval

Thierry Dorval

Head of Data Sciences & Data Management, Servier
Venkatesh Pilla Reddy

Venkatesh Pilla Reddy

Director of Clinical Pharmacology and Pharmacometrics, Astrazeneca

Alexander Hillisch

Head of Global CADD, UCB
Alexander Hillisch

Alexander Hillisch is Head of Global CADD at UCB,. His team supports small molecule and biologics drug discovery in cardiology with computational chemistry, chemoinformatics, machine learning, in silico ADMET and structural bioinformatics techniques.
From 1998 to 2003 he headed a research group at EnTec GmbH, Jena, Germany, a subsidiary of Schering AG, Berlin. There he was project manager in preclinical research and involved in the computer-aided design and pharmacological characterization of drugs against gynecological diseases and cancer.
He conducted his Ph.D. thesis at the Institute of Molecular Biotechnology (IMB), Jena in the area of biophysics (NMR, FRET) and molecular modeling. Alexander Hillisch received his Ph.D. in Biochemistry with Prof. Peter Schuster in 1998 and his diploma in Pharmacy in 1995 from the University of Vienna, Austria.
He is co-author of 44 research papers, 2 books and 62 pharmaceutical compound patents which led to 6 clinical development candidates. Alexander teaches “Molecular pharmacology and Drug Design” at the University of Cologne from which he received a honorary professorship in 2010.
 

Chris Murray

SVP Discovery Technology, Astex Pharmaceuticals
Chris Murray

Chris Murray studied for his undergraduate degree and doctorate at the University of Cambridge. After a post-doc at Indiana University, he joined the Biotech company, Protherics, where he helped develop docking methods and applied structure based drug design to serine proteases such as Factor Xa. In 2000 he joined Astex Pharmaceuticals where he now serves as SVP of Informatics. At Astex, he has been heavily involved in establishing fragment-based approaches to drug discovery and he has acted as project leader on a number of drug discovery projects including the beta-secretase, hsp90, FGFR, DDR and ERK programs.

Darren Green

Head of Cheminformatics & Data Science, Senior Fellow, GSK
Darren Green

Darren Green is Director of Molecular Design and Senior Fellow, GlaxoSmithKline. Based at Stevenage, his group specialises in the application of molecular design, data analysis, predictive modelling and chemoinformatics methods to drug discovery. Darren also leads the Compound Collection Enhancement strategy for GSK.
Darren has a PhD in Theoretical Chemistry from the University of Manchester. He is a Fellow of the Royal Society of Chemistry and chair of the Advisory Board for the Hartree Centre, the UK national laboratory for high performance computing, simulation and cognitive science.
 

Ed Addison

Chairman and CEO, Cloud Pharmaceuticals
Ed Addison

Haruna Iwaoka

Senior Director, Astellas Pharma
Haruna Iwaoka

Haruna Iwaoka is a Senior Director of Advanced Modeling & Assay-Discovery Intelligence, Astellas Pharma Inc. She leads digital transformation of drug testing platforms leveraging AI and robotics. She received the Ph.D. degrees in agricultural chemistry from Tokyo University of Agriculture, in 2019. She joined Yamanouchi Pharma (Former Astellas) after graduate school of Tokyo University of Agriculture in 1994. Ever since she had been engaged in target discovery in drug discovery research, assay development in compound screening and assay using iPSCs. Recently, she has attracted worldwide attention, such as the development of new platform "Mahol-A-Ba" (SLAS Technol. 2021;26(5): 441-453 )

Jag Heer

Director of Medicinal Chemistry, UCB
Jag Heer

Jag carried out postdoctoral research with Professor Steve Ley, FRS, working on the total synthesis of rapamycin. In 1997 he joined SmithklineBeecham as a medicinal chemist. In 2009 he joined UCB in Belgium as Director of Medicinal Chemistry working on CNS projects. In 2015 he relocated to UCB Slough to work on immunology and inflammation NCE projects. He has a broad range of interests from hit identification to candidate selection, working at the interface of computational drug design, cheminformatics, and medicinal chemistry. He is associated with delivering clinical candidates in a number of therapeutic areas including CNS and cardiovascular disease and is a fellow of the Royal Society of Chemistry.

Jan Wenzel

Scientist Computational and Systems Toxicology, Sanofi-Aventis Deutschland GmbH
Jan Wenzel

Jennifer Knight

Director, Schrödinger
Jennifer Knight

Jennifer L Knight is Senior Principal Scientist at Schrödinger, based in NYC. She received her Ph.D. in Chemistry & Chemical Biology with Ron Levy from Rutgers University and undertook postdoctoral training with Charles Brooks III at The Scripps Research Institute and the University of Michigan. Jennifer joined the Scientific Development team at Schrödinger in 2012 and for the past seven years has been a member of the Schrödinger Therapeutics Group. She spearheads modeling teams employing the full spectrum of in silico strategies, including free energy calculations and machine learning approaches. She is a champion for workflow optimization and their implementation at-scale to help drive drug discovery projects forward.

Martin Akerman

Chief Technical Officer, Envisagenics
Martin Akerman

Dr. Martin Akerman is the inventor of SpliceCore®, Envisagenics’ flagship platform born of his vision of applying machine learning to RNA information and discovering new drug targets in areas of unmet need. Martin trained as a postdoctoral fellow with Dr. Adrian Krainer at Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. Dr. Akerman received his PhD in Bioinformatics from Technion, Israel Institute of Technology, where he studied how RNA splicing can boost functionality of the human genome and trigger diseases.

 

Martin-Immanuel Bittner

Co-Founder and CEO, Arctoris
Martin-Immanuel Bittner

Martin-Immanuel Bittner, MD, DPhil, FRSA is the Chief Executive Officer of Arctoris, the drug discovery platform company that he co-founded in Oxford. Martin graduated as a medical doctor from the University of Freiburg in Germany, followed by his DPhil in Oncology as a Rhodes scholar at the University of Oxford. He has extensive research experience covering both clinical trials and preclinical drug discovery and is an active member of several leading cancer research organizations, including EACR, AACR, and ESTRO. In recognition of his research achievements, he has been elected as a member of the Young Academy of the German National Academy of Sciences and of Sigma Xi.

Matthew Segall

Chief Executive Officer, Optibrium
Matthew Segall

Matthew Segall is CEO of Optibrium. He has an MSc in Computation from the University of Oxford and a PhD in theoretical physics from the University of Cambridge. Since 2001, Matthew has led teams developing predictive models and intuitive decision-support and visualization tools for drug discovery. Matt has published over 40 peer-reviewed papers and book chapters on computational chemistry, cheminformatics and drug discovery. In 2009 he led a management buyout of the StarDrop™ business to found Optibrium, which develops novel technologies and ground-breaking AI software and services, including Cerella™ and Inspyra™, that improve the efficiency and productivity of drug discovery.

Matthias Frech

Director Molecular Interactions and Biophysics, Merck KGaA
Matthias Frech

Paul Beroza

Distinguished Scientist, Genentech
Paul Beroza

Paul, a Distinguished Scientist in Computational Drug Discovery at Genentech, has over 20 years experience in computer-aided drug design and informatics in pharmaceutical research environments. He received his Ph.D. in Biophysics from UC San Diego and did postdoctoral work at the Scripps Research Institute. Before joining Genentech, he held several positions in Bay Area pharmaceutical companies including Senior Scientist Dupont Pharmaceuticals Research Labs, Director of Computational Sciences Telik, Inc. and Director of Computer-Aided Drug Design and Research Informatics Elan Pharmaceuticals. He has consulted in the areas of molecular modeling and 3D visualization technology and has over 40 patents and publications.

Simone Fulle

Head of Molecular modelling & Design, Novo Nordisk A/S
Simone Fulle

Steve Gardner

CEO, PrecisionLife
Steve Gardner

Steve is a serial technology entrepreneur with over 30 years’ experience developing and commercializing ground-breaking data science and informatics in the healthcare, life sciences and agri-food sectors.

Never afraid to innovate, Steve has an established track record in building world-class companies, teams and products working at senior levels in the UK, EU and US for Fortune 500 and start-up companies.

He is a former Global Director of Research Informatics for Astra A/B and has consulted with drug discovery and safety teams in over 20 biopharma companies.

 

Thierry Dorval

Head of Data Sciences & Data Management, Servier
Thierry Dorval

Thierry Dorval received a B.S. degree in theoretical physic and obtained a Ph.D. in image processing and artificial intelligence at Pierre & Marie Curie University, Paris, France. He then joined the Institut Pasteur Korea in 2005 first as researcher in biological image analysis then as a group leader specialized in High Content Screening applied to cellular differentiation as well as toxicity prediction. In 2012 he joined AstraZeneca, UK, where he was leading the Image and Data Analytics team. His activities were about developing and advising on quantitative image and data analysis solutions in support of high content phenotypic screens.
In 2015 he joined Servier, France, first as leader of the High Content Screening group within CentEX CPCB and then as Head of Data Science Lab, working on phenotypic approaches to improve drug discovery pipeline efficiency using high content and machine learning strategies.
 

Venkatesh Pilla Reddy

Director of Clinical Pharmacology and Pharmacometrics, Astrazeneca
Venkatesh Pilla Reddy

sponsors

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

clock

9:10

Applying AI/ML in the drug discovery processes from hypothesis testing to preclinical screening

Darren Green, Head of Cheminformatics & Data Science, Senior Fellow, GSK

• Overcoming the challenges currently facing pharmaceutical R&D programmes with data science and AI
• Opportunities for data analysis and predictive modelling in drug discovery
• Profitable applications to translate AI/ML from the lab to the clinic
• Open data sharing? - The importance of long-term planning
 

clock

9:50

Deep learning to predict pharmacokinetics from limited ADME data: real-world applications

Matthew Segall, Chief Executive Officer, Optibrium

  • An introduction to the challenges we face using data in drug discovery 
  • Deep learning imputation, and how it can be applied in the context of pharmacokinetics 
  • Real-life case studies from our collaborators using deep learning in action for successful pharmacokinetics prediction 
  • An overview of Optibrium’s Cerella AI software

     

  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Transforming CNS and Oncology treatments with fragment-based drug discovery

    Chris Murray, SVP Discovery Technology, Astex Pharmaceuticals

  • Implementing the PyramidTM platform for fragment-based drug discovery
  • Application of machine learning to structure-based drug design
  • Case study data from Astex’s Oncology and CNS programmes

     

  • clock

    11:40

    Advancing a pipeline of drug discovery programs using diverse machine learning modeling strategies

    Jennifer Knight, Director, Schrödinger

  • Efficient profiling of large chemical space using active learning: from virtual screens to free energy calculations
  • Leveraging experimental data for enhancing ADMET profiles in lead optimization
  • Training DFT-quality potentials for accurate predictions of formulations
     
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    Exploration of Chemical Space for Drug Lead Discovery and Optimization

    Paul Beroza, Distinguished Scientist, Genentech

  • Strategies for chemical space exploration
  • Large-scale structure-based virtual screening
  • Generative design strategies for drug lead discovery and optimization
  • Characteristics of AI-generated latent chemical spaces
  • clock

    14:00

    Maximising potential for drug discovery approaches with holistic structure-based approaches

    Alexander Hillisch, Head of Global CADD, UCB

  • Comparison of the holistic workflow to traditional processes and the role that AI/ML has played to develop this
  • ML models for predictions based on experimental ADMET and chemical synthesis data
  • Application examples from active drug discovery projects
  • Computational hit-finding experiments- The importance of public-private partnership
  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    Improving oligonucleotide molecular design using knowledge graphs

    Thierry Dorval, Head of Data Sciences & Data Management, Servier

  • Optimising drug discovery using computational approaches across organs
  • Case Studies from Servier’s drug design approach 
  • Ensuring adverse effect identification using AI approaches
  • Maximizing translatability to clinical data- The future of Knowledge Graph use
  • clock

    15:50

    Advancing precision therapeutics with the integration of patient data, biomarkers, and AI

    Ed Addison

    Ed Addison, Chairman and CEO, Cloud Pharmaceuticals

  • Developing a novel approach to treatment plans with the augmentation of AI and big data screening
  • How the cloud pharmaceuticals technology considers traditional targeted therapeutics, but also polypharmacy, repurposing, and modulated biology discovery paradigms to implement with AI
  • Eliminating the need for drug design programmes with strategic implementation of AI for drug repositioning
  • Case Study results from Cloud Pharma’s partnerships with Drug Logic and Perthera
  • clock

    16:30

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    clock

    9:10

    In silico peptide & protein design

    Simone Fulle

    Simone Fulle, Head of Molecular modelling & Design, Novo Nordisk A/S

  • Peptides as therapeutic modalities and role of Molecular Modelling
  • Where we are and want to be when it comes to ML-based predictions for proteins and antibodies
  • Requirements to be a data driven company that utilizes ML
  • clock

    9:50

    Application of AI and Quantum Chemical Methods in a Pharmaceutical Environment

    Jan Wenzel

    Jan Wenzel, Scientist Computational and Systems Toxicology, Sanofi-Aventis Deutschland GmbH

  • ADME-Tox prediction using deep neural networks (DNN)
  • Comparison of different DNN methods
  • Applicability in a pharmaceutical environment
  • Computational quantum chemistry approach to assess the reactivity of N-Nitrosamine impurities
     
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Patient-focused precision medicine: creating better treatment options for unmet medical needs

    Steve Gardner, CEO, PrecisionLife

  • Discovering novel drug targets with genetic linkage for complex diseases
  • Precision repositioning of existing drugs to treat additional diseases
  • Biomarkers to select the right patients for successful clinical trials
  • Accurately diagnosing patients and selecting the most effective medicines
     
  • clock

    11:40

    Closing the loop by combining wet lab automation and machine learning for accelerated program progression from target to hit, lead, and candidate

    Martin-Immanuel Bittner, Co-Founder and CEO, Arctoris

  • The Design-Make-Test-Analyse cycle is central for drug discovery, driving compound design and selection
  • Right now, cycle times are long, and only a fraction of drug-like chemical space is being evaluated
  • Combining wet lab automation with machine learning allows us to close the loop in the discovery phase, with rapid, iterative data generation synergizing with a more efficient exploration of a wider chemical space
  • This enables an accelerated progression from target to high-quality hit, lead, and candidate
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    Cellular Drug Discovery Platform “Mahol-A-Ba” Integrating Humans, AI, and Robots

    Haruna Iwaoka, Senior Director, Astellas Pharma

  • Integrating humans, AI and robots enables the development of high-quality drugs in a shorter time 
  • Developed cellular drug discovery platform “Mahol-A-Ba”, to utilize iPS cells for drug discovery
  • How “Mahol-A-Ba” enable us to do things that were previously impossible with human power alone
  • How to provide clearer and more precise results utilizing AI in our image processing technology

     

  • clock

    14:00

    AI/ML Driven Discovery of Splicing Derived Neoantigens

    Martin Akerman, Chief Technical Officer, Envisagenics

  • AI/ML Driven Discovery of Splicing Derived Neoantigens
  • Transparent guidelines to development of AI/ML features  to allow more streamlined discovery feedback and processes
  • Introduction to Envisageincs’ SpliceIO platform: machine learning ensemble for the identifi cation of RNA splicing derived  neoantigens
  • Case study: novel transmembrane neopeptide in triple negative breast cancer (ENV-21)
  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    Operation Moonshoot- How AI based CADD helped the search for Covid-19 treatments

    Jag Heer, Director of Medicinal Chemistry, UCB

  • Harnessing the power of CADD to rapidly decode complex biology
  • Bridging knowledge- and structure-based approaches to enable greater predictive performance and expedite drug discovery cycle
  • Integration of data-driven research with wise experimental target validation approaches
  • Effective international collaboration with AI drug design

     

  • clock

    15:50

    How was AI used for predicting drug interaction properties?

    Venkatesh Pilla Reddy

    Venkatesh Pilla Reddy, Director of Clinical Pharmacology and Pharmacometrics, Astrazeneca

  • The current state of play for Machine Learning predictions
  • Comparison of machine learning techniques
  • Strategic applications for AI and ML
  • Case Study for Safety Predictions
     
  • clock

    16:30

    Chairman’s Closing Remarks and Close of Day Two


    Head of Global CADD
    UCB
    SVP Discovery Technology
    Astex Pharmaceuticals
    Head of Cheminformatics & Data Science, Senior Fellow
    GSK
    Chairman and CEO
    Cloud Pharmaceuticals
    Senior Director
    Astellas Pharma
    Director of Medicinal Chemistry
    UCB
    Scientist Computational and Systems Toxicology
    Sanofi-Aventis Deutschland GmbH
    Director
    Schrödinger
    Chief Technical Officer
    Envisagenics
    Co-Founder and CEO
    Arctoris
    Chief Executive Officer
    Optibrium
    Director Molecular Interactions and Biophysics
    Merck KGaA
    Distinguished Scientist
    Genentech
    Head of Molecular modelling & Design
    Novo Nordisk A/S
    CEO
    PrecisionLife
    Head of Data Sciences & Data Management
    Servier
    Director of Clinical Pharmacology and Pharmacometrics
    Astrazeneca

    Sponsors

    Exhibitors

    Official Media Partner

    Supporters

    Preliminary Attendees List

    Download

    Past Attendee List

    Download

    Speaker Biographies

    Download

    Chair Letter

    Download

    Short Agenda

    Download

    Full Agenda

    Download

    Sponsors


    Optibrium

    Sponsors
    http://www.optibrium.com

    Optibrium develops cutting-edge software for small molecule design, optimisation and data analysis. Cerella™, Optibrium’s proven AI, guides successful drug discovery, generating valuable insights from your data, whilst Inspyra™ combines your expert chemistry knowledge with the exploratory power of generative methods to create, evaluate and optimise novel compound ideas.



    Schrödinger

    Sponsors
    http://www.schrodinger.com

    Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.


    Exhibitors


    OpenEye Scientific Software

    Exhibitors
    http://www.eyesopen.com/

    OpenEye has built a solid reputation as a scientific leader in the field of molecular design based on two decades of delivering useful applications and programming toolkits. Our scientific approach has focussed on the power of molecular 3D structure to inform and guide, in particular via the concept of shape similarity. We have changed industry perception of what is possible with the speed, robustness and scalability of our tools and have recently built these into a ground-up, cloud-native platform, Orion. Combining unlimited computation and storage with powerful tools for data sharing, visualization and analysis in an open development platform, Orion offers unprecedented capabilities for drug discovery and optimization.

    Media Partners


    Drug Discovery Today

    Official Media Partner
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.

    Media Partners


    Mcule

    Supporters
    https://mcule.com/



    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    IPI

    Supporters
    http://www.ipimediaworld.com

    IPI – International Pharmaceutical Industry Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    SciDoc Publishers

    Supporters
    http://www.scidoc.org

    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.